Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Framework vs Spry

Framework
Graded #230

Higher grade

vs+8.299999999999997
Spry
Graded #409

Lower grade

The verdict

Framework takes it — 65.1/100 to 56.8/100.

Framework grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Framework is a personalized-plan GLP-1 telehealth platform offering compounded semaglutide and tirzepatide with doctor-guided treatment selection.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFramework +26
80
54
Dose & formulationEven
64
64
Clinical oversightFramework +17
72
55
Labs & monitoringEven
52
52
FulfillmentSpry +4
57
61
Contract termsSpry +14
41
55
Framework · left barSpry · right bar

The numbers

MetricFrameworkSpry
WeighScore65.1/10056.8/100
GradeCC
Scorecard rank#230#409
Semaglutide$100/mo (starting dose, compounded)$199/mo (starting dose, compounded)
Tirzepatide$100/mo (starting dose, compounded)$299/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Framework

Graded #230 · C

Strengths

  • Named 503B pharmacy partner (The Pharmacy Hub) disclosed — the FDA-registered outsourcing-facility pathway, distinct from 503A
  • Publishes the FDA compounded-medication disclaimer
  • $25/week pricing (~$100/mo) is among the most aggressive in the directory
  • $0 membership fees
  • Phone support published, toll-free (888) 412-0666

Where it loses points

  • LegitScript ID / certification not shown on the homepage
  • States-served list not disclosed
  • Medical director / clinical leadership not disclosed
  • Corporate legal entity not disclosed (no footer copyright)
  • Governing law / arbitration venue not stated
Spry

Graded #409 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard